Opdivo Qvantig

Generic name: nivolumab and hyaluronidase-nvhy

Used for: Non-small cell lung cancer · Melanoma · Kidney cancer (renal cell carcinoma) · Bladder and urinary tract cancer (urothelial carcinoma) · Stomach and esophageal cancer · Liver cancer (hepatocellular carcinoma) · Colorectal cancer (MSI-H or dMMR) · Head and neck cancer (squamous cell) · 7 more

How do you pay?

How to pay the least

Ask for the cash price

Opdivo Qvantig

Opdivo Qvantig is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Opdivo Qvantig’s cash price, and one or two other pharmacies too.
  2. Opdivo Qvantig’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Bristol Myers Squibb Patient Assistance Foundation (BMSPAF). Or call 1-800-736-0003.

See if you qualify 

Compare every option

Question
Brand nameOpdivo Qvantig
Authorized genericnivolumab and hyaluronidase-nvhy
Regular genericnivolumab and hyaluronidase-nvhy
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Opdivo Qvantig?
The original
–
–

Brand nameThe maker’s card

BMS Access Support Co-Pay Assistance Program

Savings card from Bristol Myers Squibb

No insuranceNeeds insuranceNo cash price listed.
Insurance $0 a dose

Sign up on bmsaccesssupport.com 

Or call 1-800-861-0048.

In the maker’s words

“$0 Co-pay per dose…”

From the maker’s offer on bmsaccesssupport.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Opdivo Qvantig itself, from the same company, sold without the brand name, and usually for less. For now Opdivo Qvantig is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Opdivo Qvantig is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of:

Renal Cell Carcinoma (RCC)

  • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma.
  • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib.
  • adult patients with advanced RCC who have received prior anti-angiogenic therapy.

Melanoma

  • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma.
  • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma.
  • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.

Non-Small Cell Lung Cancer (NSCLC)

  • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
  • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery.
  • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC.

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy.

Urothelial Carcinoma (UC)

  • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC.
  • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
  • adult patients with locally advanced or metastatic UC who:
    • have disease progression during or following platinum-containing chemotherapy.
    • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Colorectal Cancer (CRC)

  • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with intravenous nivolumab and ipilimumab.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
  • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.

Hepatocellular Carcinoma (HCC)

  • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
  • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab.
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC.

Esophageal Cancer

  • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
  • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1).
    • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC.
  • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.

Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma

  • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.

Source: the FDA label for Opdivo Qvantig (E.R. Squibb & Sons, L.L.C.), May 12, 2026. Full label on DailyMed 

Good to know

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/opdivo-qvantig/